Participants were drawn from the WRAP, a longitudinal study designed to identify midlife factors associated with the development of Alzheimer’s disease.39 (link),40 (link) Enrolment of participants began in 2001, with the first follow-up visit occurring 2 to 4 years after the baseline visit and all additional visits occurring at 2-year intervals thereafter. WRAP participants were free of dementia at enrolment (mean age 54 years). All study procedures were approved by the University of Wisconsin School of Medicine and Public Health Institutional Review Board and are in concordance with the Declaration of Helsinki.
At each study visit, participants completed comprehensive neuropsychological assessment and multiple questionnaires related to a broad array of factors, including lifestyle, modifiable risk factors, medical history and memory functioning. Sleep measures were added in two stages to the WRAP assessment protocol. To be eligible for the primary analyses, participants needed to have completed the full set of sleep measures at least once and be free of dementia at time of sleep assessment (n = 619). To be eligible for secondary analyses, participants needed to have completed at least one of the sleep questionnaires described below and had completed a Pittsburgh Compound B (PiB) PET scan.
At each study visit, participants completed comprehensive neuropsychological assessment and multiple questionnaires related to a broad array of factors, including lifestyle, modifiable risk factors, medical history and memory functioning. Sleep measures were added in two stages to the WRAP assessment protocol. To be eligible for the primary analyses, participants needed to have completed the full set of sleep measures at least once and be free of dementia at time of sleep assessment (n = 619). To be eligible for secondary analyses, participants needed to have completed at least one of the sleep questionnaires described below and had completed a Pittsburgh Compound B (PiB) PET scan.
Free full text: Click here
